The Metabolic Dietary Disorders Association (MDDA), along with patients and clinicians, are profoundly disappointed by Moderna’s sudden decision to withdraw the Australian clinical trial for Methylmalonic Acidemia (MMA) and are calling for Moderna to urgently reinstate the trial.
Moderna’s establishment of trial sites in Melbourne and Sydney in 2024 was positive news for clinicians as well as patients and families living with MMA, a rare disease, who currently have no treatments and face kidney and liver transplants as well as neurological impairment. The community have been anxiously preparing for the trial to start, with one family moving interstate to participate. This mRNA therapy trial offered hope to families who previously had no treatment options.
To read the full Media Press Release please click the link below. Should you have any comments please email [email protected]